SIMULTANEOUS ACTION OF THE FLAVONOID QUERCETIN ON CYTOCHROME P450 (CYP) 1A2, CYP2A6, N-ACETYLTRANSFERASE AND XANTHINE OXIDASE ACTIVITY IN HEALTHY VOLUNTEERS

SUMMARY 1 Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N‐acetyltransferase (NAT2) and xanthine ox...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental pharmacology & physiology Vol. 36; no. 8; pp. 828 - 833
Main Authors Chen, Yao, Xiao, Peng, Ou-Yang, Dong-Sheng, Fan, Lan, Guo, Dong, Wang, Yi-Nan, Han, Yang, Tu, Jiang-Hua, Zhou, Gan, Huang, Yuan-Fei, Zhou, Hong-Hao
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.08.2009
Subjects
Adolescent
Adult
Aryl Hydrocarbon Hydroxylases - metabolism
Arylamine N-Acetyltransferase - metabolism
Caffeine - metabolism
Caffeine - pharmacokinetics
Caffeine - urine
Cross-Over Studies
CYP1A2
CYP2A6
Cytochrome P-450 CYP1A2 - metabolism
Cytochrome P-450 CYP2A6
Dose-Response Relationship, Drug
Drug Interactions
Humans
Inactivation, Metabolic
Male
N-acetyltransferase
quercetin
Quercetin - administration & dosage
Quercetin - pharmacology
Time Factors
xanthine oxidase
Xanthine Oxidase - metabolism
Young Adult
Online AccessGet full text

Cover

Abstract SUMMARY 1 Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N‐acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. 2 Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. 3 In the quercetin‐treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1–29.8%; P = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2–34.5%; P = 0.002), NAT2 (by 88.7%; 95% CI, 7.1–160.2%; P = 0.010) and XO activity (by 15.0%; 95% CI, 1.6–21.6%; P = 0.007). Plasma Cmax and the AUC(0–24 h) of 1,7‐dimethylxanthine were decreased by 17.2% (95% CI, 6.4–28.0%; P = 0.024) and 16.2% (95% CI, 3.9–28.5%; P = 0.032), respectively. The urinary excretion of 1,7‐dimethylxanthine and 1‐methylxanthine was significantly decreased by 32.4% (95% CI, 2.5–62.1%; P = 0.036) and 156.1% (95% CI, 53.3–258.9%; P = 0.004), respectively. The urinary excretion of 1,7‐dimethylurate and 1‐methylurate was increased by 82.9% (95% CI, 56.0–165.4%; P = 0.030) and 97.8% (95% CI, 12.1–183.5%; P = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5‐acetylamino‐6‐formylamino‐3‐methyluracil between the two study phases. 4 The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7‐dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo.
AbstractList Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N ‐acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. In the quercetin‐treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1–29.8%; P  = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2–34.5%; P  = 0.002), NAT2 (by 88.7%; 95% CI, 7.1–160.2%; P  = 0.010) and XO activity (by 15.0%; 95% CI, 1.6–21.6%; P  = 0.007). Plasma C max and the AUC (0–24 h) of 1,7‐dimethylxanthine were decreased by 17.2% (95% CI, 6.4–28.0%; P  = 0.024) and 16.2% (95% CI, 3.9–28.5%; P  = 0.032), respectively. The urinary excretion of 1,7‐dimethylxanthine and 1‐methylxanthine was significantly decreased by 32.4% (95% CI, 2.5–62.1%; P  = 0.036) and 156.1% (95% CI, 53.3–258.9%; P  = 0.004), respectively. The urinary excretion of 1,7‐dimethylurate and 1‐methylurate was increased by 82.9% (95% CI, 56.0–165.4%; P  = 0.030) and 97.8% (95% CI, 12.1–183.5%; P  = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5‐acetylamino‐6‐formylamino‐3‐methyluracil between the two study phases. The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7‐dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo .
1. Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug-metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. 2. Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. 3. In the quercetin-treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1-29.8%; P = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2-34.5%; P = 0.002), NAT2 (by 88.7%; 95% CI, 7.1-160.2%; P = 0.010) and XO activity (by 15.0%; 95% CI, 1.6-21.6%; P = 0.007). Plasma C(max) and the AUC((0-24 h)) of 1,7-dimethylxanthine were decreased by 17.2% (95% CI, 6.4-28.0%; P = 0.024) and 16.2% (95% CI, 3.9-28.5%; P = 0.032), respectively. The urinary excretion of 1,7-dimethylxanthine and 1-methylxanthine was significantly decreased by 32.4% (95% CI, 2.5-62.1%; P = 0.036) and 156.1% (95% CI, 53.3-258.9%; P = 0.004), respectively. The urinary excretion of 1,7-dimethylurate and 1-methylurate was increased by 82.9% (95% CI, 56.0-165.4%; P = 0.030) and 97.8% (95% CI, 12.1-183.5%; P = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5-acetylamino-6-formylamino-3-methyluracil between the two study phases. 4. The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7-dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo.1. Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug-metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. 2. Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. 3. In the quercetin-treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1-29.8%; P = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2-34.5%; P = 0.002), NAT2 (by 88.7%; 95% CI, 7.1-160.2%; P = 0.010) and XO activity (by 15.0%; 95% CI, 1.6-21.6%; P = 0.007). Plasma C(max) and the AUC((0-24 h)) of 1,7-dimethylxanthine were decreased by 17.2% (95% CI, 6.4-28.0%; P = 0.024) and 16.2% (95% CI, 3.9-28.5%; P = 0.032), respectively. The urinary excretion of 1,7-dimethylxanthine and 1-methylxanthine was significantly decreased by 32.4% (95% CI, 2.5-62.1%; P = 0.036) and 156.1% (95% CI, 53.3-258.9%; P = 0.004), respectively. The urinary excretion of 1,7-dimethylurate and 1-methylurate was increased by 82.9% (95% CI, 56.0-165.4%; P = 0.030) and 97.8% (95% CI, 12.1-183.5%; P = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5-acetylamino-6-formylamino-3-methyluracil between the two study phases. 4. The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7-dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo.
SUMMARY 1 Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N‐acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. 2 Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. 3 In the quercetin‐treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1–29.8%; P = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2–34.5%; P = 0.002), NAT2 (by 88.7%; 95% CI, 7.1–160.2%; P = 0.010) and XO activity (by 15.0%; 95% CI, 1.6–21.6%; P = 0.007). Plasma Cmax and the AUC(0–24 h) of 1,7‐dimethylxanthine were decreased by 17.2% (95% CI, 6.4–28.0%; P = 0.024) and 16.2% (95% CI, 3.9–28.5%; P = 0.032), respectively. The urinary excretion of 1,7‐dimethylxanthine and 1‐methylxanthine was significantly decreased by 32.4% (95% CI, 2.5–62.1%; P = 0.036) and 156.1% (95% CI, 53.3–258.9%; P = 0.004), respectively. The urinary excretion of 1,7‐dimethylurate and 1‐methylurate was increased by 82.9% (95% CI, 56.0–165.4%; P = 0.030) and 97.8% (95% CI, 12.1–183.5%; P = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5‐acetylamino‐6‐formylamino‐3‐methyluracil between the two study phases. 4 The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7‐dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo.
1. Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug-metabolising enzymes. The aim of the present study was to investigate the effects of quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase (NAT2) and xanthine oxidase (XO) activity in healthy volunteers using caffeine as a probe drug. 2. Twelve unrelated, healthy volunteers were recruited to the study. There were two phases to the study; in the first phase, each subject was given a single oral dose of caffeine (one 100 mg capsule) with 150 mL water; in the second phase, each subject was give a 500 mg quercetin capsule once daily for 13 continuous days and was coadministered a 100 mg caffeine capsule on the 13th day. Urinary caffeine metabolite ratios were used as indicators of the activity of CYP1A2, CYP2A6, NAT2 and XO. The pharmacokinetics of caffeine and its metabolites were determined by HPLC. 3. In the quercetin-treated group, CYP1A2 activity was decreased by 10.4% (95% confidence interval (CI), 1.1-29.8%; P = 0.039), whereas increases were observed in CYP2A6 (by 25.3%; 95% CI, 6.2-34.5%; P = 0.002), NAT2 (by 88.7%; 95% CI, 7.1-160.2%; P = 0.010) and XO activity (by 15.0%; 95% CI, 1.6-21.6%; P = 0.007). Plasma C(max) and the AUC((0-24 h)) of 1,7-dimethylxanthine were decreased by 17.2% (95% CI, 6.4-28.0%; P = 0.024) and 16.2% (95% CI, 3.9-28.5%; P = 0.032), respectively. The urinary excretion of 1,7-dimethylxanthine and 1-methylxanthine was significantly decreased by 32.4% (95% CI, 2.5-62.1%; P = 0.036) and 156.1% (95% CI, 53.3-258.9%; P = 0.004), respectively. The urinary excretion of 1,7-dimethylurate and 1-methylurate was increased by 82.9% (95% CI, 56.0-165.4%; P = 0.030) and 97.8% (95% CI, 12.1-183.5%; P = 0.029), respectively. No changes were observed in the urinary excretion of caffeine and 5-acetylamino-6-formylamino-3-methyluracil between the two study phases. 4. The results of the present study indicate that quercetin inhibits CYP1A2 function, but enhances CYP2A6, NAT2 and XO activity. Simultaneously, some pharmacokinetic parameters relating to 1,7-dimethylxanthine were affected by quercetin. Thus, we conclude that quercetin affects CYP1A2, CYP2A6, NAT2 and XO activity in vivo.
Author Wang, Yi-Nan
Zhou, Gan
Xiao, Peng
Guo, Dong
Ou-Yang, Dong-Sheng
Han, Yang
Zhou, Hong-Hao
Chen, Yao
Tu, Jiang-Hua
Fan, Lan
Huang, Yuan-Fei
Author_xml – sequence: 1
  givenname: Yao
  surname: Chen
  fullname: Chen, Yao
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 2
  givenname: Peng
  surname: Xiao
  fullname: Xiao, Peng
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 3
  givenname: Dong-Sheng
  surname: Ou-Yang
  fullname: Ou-Yang, Dong-Sheng
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 4
  givenname: Lan
  surname: Fan
  fullname: Fan, Lan
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 5
  givenname: Dong
  surname: Guo
  fullname: Guo, Dong
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 6
  givenname: Yi-Nan
  surname: Wang
  fullname: Wang, Yi-Nan
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 7
  givenname: Yang
  surname: Han
  fullname: Han, Yang
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 8
  givenname: Jiang-Hua
  surname: Tu
  fullname: Tu, Jiang-Hua
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 9
  givenname: Gan
  surname: Zhou
  fullname: Zhou, Gan
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 10
  givenname: Yuan-Fei
  surname: Huang
  fullname: Huang, Yuan-Fei
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
– sequence: 11
  givenname: Hong-Hao
  surname: Zhou
  fullname: Zhou, Hong-Hao
  organization: Institute of Clinical Pharmacology, Hunan Medical University, Central South University, Changsha, Hunan, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19215233$$D View this record in MEDLINE/PubMed
BookMark eNqNkV1v0zAYhS00xLrBX0C-A6Sl-COxkwuQTOoukTKna9zSXllp5kjp-jGSVuv-y34syTp6wQ34xpbPec4rvecCnG22GwsAxKiP2_N12ceuixzMfNwnCAV95GHP7x_egN5JOAM9RJHnYJ-jc3DRNEuEkIcYfQfOcUCwRyjtgecsvpkkWiiZTjIoQh2nCqZDqCMJh4mYpiqNB_B2Iseh1HErKRjOdRpG4_RGwpHrIfg5nI--QCzIVSuNiGBXUDmitc8TPRYqG8qxyCQUagBnQukoVhKms3jw8tkOnMZ6DtvoSIpER3M4TZOJ0lKOs_fgbZmvGvvh9b4Eeih1GDlJeh2HInEKjxDf4aTktFj4dOHbklB851LMc4RzsuCc-bxwXcbKkrsk94vABpi5vGw3xtx8EQSUXoJPx9iHevtrb5udWVdNYVerfGO3-8ZwSgPGfNY5P74694u1vTMPdbXO6yfzZ5-t4fvRUNTbpqltaYpql--q7WZX59XKYGS6As3SdD2ZrifTFWheCjSHNsD_K-A049_otyP6WK3s039zJpSj7tXyzpGvmp09nPi8vjeMU-6Zn-razIhGP7Lk1mD6Gx8Hstk
CitedBy_id crossref_primary_10_3390_pharmaceutics10040277
crossref_primary_10_3390_nu6125392
crossref_primary_10_1155_2015_760689
crossref_primary_10_1124_pr_117_014407
crossref_primary_10_1016_j_fct_2016_12_021
crossref_primary_10_1080_10408398_2023_2299329
crossref_primary_10_1586_ecp_12_39
crossref_primary_10_1002_ptr_6365
crossref_primary_10_3109_03602530903286476
crossref_primary_10_1007_s00204_020_02936_7
crossref_primary_10_1016_j_clinthera_2014_08_012
crossref_primary_10_1111_bcpt_13121
crossref_primary_10_3390_molecules24050940
crossref_primary_10_1016_j_radonc_2011_10_023
crossref_primary_10_4236_ojpm_2012_21001
crossref_primary_10_1016_j_isci_2024_111298
crossref_primary_10_1007_s40262_019_00737_5
crossref_primary_10_1213_ANE_0000000000004875
crossref_primary_10_1345_aph_1M533
crossref_primary_10_1017_S0007114512003005
crossref_primary_10_1002_ptr_5220
crossref_primary_10_3389_fphar_2021_752826
crossref_primary_10_5551_jat_31765
crossref_primary_10_3390_nu14040768
crossref_primary_10_2133_dmpk_DMPK_10_RG_107
crossref_primary_10_1016_j_jff_2019_103624
crossref_primary_10_3762_bjoc_13_243
crossref_primary_10_1016_j_dmpk_2021_100397
crossref_primary_10_1016_j_fct_2019_05_013
crossref_primary_10_1155_2014_405071
crossref_primary_10_3923_pjbs_2021_1217_1225
crossref_primary_10_1021_jf1049529
crossref_primary_10_3390_molecules27217222
crossref_primary_10_3892_mmr_2016_5616
crossref_primary_10_7759_cureus_66959
crossref_primary_10_3390_nu7042947
crossref_primary_10_1021_acs_jafc_8b02839
crossref_primary_10_3390_foods10112595
crossref_primary_10_1007_s43450_022_00347_6
crossref_primary_10_1002_mnfr_201700447
crossref_primary_10_3390_ijms22010107
crossref_primary_10_4155_fmc_2017_0113
crossref_primary_10_1007_s11094_014_1050_6
crossref_primary_10_1080_13880209_2020_1738504
crossref_primary_10_1007_s10930_023_10165_x
crossref_primary_10_1016_j_bcp_2011_08_010
crossref_primary_10_1007_s00228_011_1108_2
crossref_primary_10_1007_s13277_016_5184_x
crossref_primary_10_1016_j_fitote_2015_09_018
crossref_primary_10_3389_fnut_2022_857370
crossref_primary_10_1016_j_ajps_2018_12_003
crossref_primary_10_1007_s13318_019_00560_0
crossref_primary_10_1016_j_jddst_2022_103215
Cites_doi 10.1016/j.mrfmmm.2003.08.002
10.1016/S0731-7085(01)00546-5
10.1038/clpt.1983.80
10.1016/j.ijpharm.2006.01.028
10.1016/0272-0590(92)90181-G
10.1111/j.1742-7843.2005.pto_98.x
10.1016/j.fct.2007.02.020
10.1097/00008571-199206000-00003
10.1038/clpt.1987.126
10.1016/S1383-5718(01)00267-4
10.1002/bmc.736
10.1016/j.cbi.2006.08.002
10.1093/ajcn/68.1.60
10.1207/S15327914NC441_13
10.1016/S0024-3205(02)02235-X
10.1093/ajcn/72.5.1150
10.1128/AAC.49.5.1733-1738.2005
10.1016/S0378-4347(98)00016-4
10.1042/bj3400715
10.1016/S0731-7085(01)00656-2
10.4161/cbt.4.9.1908
10.1016/S0378-4347(00)00325-X
10.1016/j.ijpharm.2004.12.004
ContentType Journal Article
Copyright 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Asia Pty Ltd
Copyright_xml – notice: 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Asia Pty Ltd
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/j.1440-1681.2009.05158.x
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1440-1681
EndPage 833
ExternalDocumentID 19215233
10_1111_j_1440_1681_2009_05158_x
CEP5158
ark_67375_WNG_X2T0BSLQ_1
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29B
2QV
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DXH
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
GWYGA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KTM
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK0
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YCJ
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c5228-72f73cb83b8ef231d4317a01a2b77687c4466ff742a8c9e91647f05164ab9933
IEDL.DBID DR2
ISSN 0305-1870
1440-1681
IngestDate Fri Jul 11 10:15:18 EDT 2025
Mon Jul 21 05:24:08 EDT 2025
Tue Jul 01 02:10:54 EDT 2025
Thu Apr 24 22:54:15 EDT 2025
Wed Jan 22 16:22:49 EST 2025
Wed Oct 30 09:56:28 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5228-72f73cb83b8ef231d4317a01a2b77687c4466ff742a8c9e91647f05164ab9933
Notes ArticleID:CEP5158
ark:/67375/WNG-X2T0BSLQ-1
istex:0CCB7C26563F29C719365EA7E91D6BA0B69E0BDA
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1681.2009.05158.x
PMID 19215233
PQID 733966863
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_733966863
pubmed_primary_19215233
crossref_citationtrail_10_1111_j_1440_1681_2009_05158_x
crossref_primary_10_1111_j_1440_1681_2009_05158_x
wiley_primary_10_1111_j_1440_1681_2009_05158_x_CEP5158
istex_primary_ark_67375_WNG_X2T0BSLQ_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2009
PublicationDateYYYYMMDD 2009-08-01
PublicationDate_xml – month: 08
  year: 2009
  text: August 2009
PublicationDecade 2000
PublicationPlace Melbourne, Australia
PublicationPlace_xml – name: Melbourne, Australia
– name: Australia
PublicationTitle Clinical and experimental pharmacology & physiology
PublicationTitleAlternate Clin Exp Pharmacol Physiol
PublicationYear 2009
Publisher Blackwell Publishing Asia
Publisher_xml – name: Blackwell Publishing Asia
References Lin SY, Tsai SJ, Wang LH, Wu MF, Lee H. Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells. Role of COX-2. Nutr. Cancer 2002; 44: 95-101.
Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 2006; 313: 144-9.
Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin. Pharmacol. Ther. 1983; 33: 591-602.
De Vries JH, Hollman PC, Meyboom S et al . Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am. J. Clin. Nutr. 1998; 68: 60-5.
Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999; 340: 715-22.
Yeh SL, Wu SH. Effects of quercetin on beta-apo-8′-carotenal-induced DNA damage and cytochrome P1A2 expression in A549 cells. Chem. Biol. Interact. 2006; 163: 199-206.
Dudka J, Jodynis-Liebert J, Korobowicz E et al . Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: An in vitro study. Basic Clin. Pharmacol. Toxicol. 2005; 97: 74-9.
Pignatelli P, Pulcinelli FM, Celestini A et al . The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am. J. Clin. Nutr. 2000; 72: 1150-5.
Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr. 2007; 21: 190-200.
Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci. 2002; 72: 227-35.
Desbrow B, Hughes R, Leveritt M, Scheelings P. An examination of consumer exposure to caffeine from retail coffee outlets. Food Chem. Toxicol. 2007; 45: 1588-92.
Rahden-Staron I, Czeczot H, Szumilo M. Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin. Mutat. Res. 2001; 498: 57-66.
Wong P, Villeneuve G, Tessier V et al . Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J. Pharmaceut. Biomed. 2002; 28: 693-700.
Caubet MS, Elbast W, Dubuc MC, Brazier JL. Analysis of urinary caffeine metabolites by HPLC-DAD. The use of metabolic ratios to assess CYP1A2 enzyme activity. J. Pharm. Biomed. Anal. 2002; 27: 261-70.
Butler MA, Lang NP, Young JF et al . Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al . Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses. Antimicrob. Agents Chemother. 2005; 49: 1733-8.
Gross M, Pfeiffer M, Martini M, Campbell D, Slavin J, Potter J. The quantitation of metabolites of quercetin flavonols in human urine. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 711-20.
Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther. 2005; 4: 949-55.
Choi JS, Li X. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int. J. Pharm. 2005; 297: 1-8.
Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998; 709: 27-34.
Bendriss EK, Markoglou N, Wainer IW. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J. Chromatogr. B Biomed. Sci. Appl. 2000; 746: 331-8.
Kang IH, Kim HJ, Oh H, Park YI, Dong MS. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat. Res. 2004; 545: 37-47.
Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam. Appl. Toxicol. 1992; 19: 423-31.
Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 1987; 42: 157-65.
2002; 27
2002; 28
2001; 498
1987; 42
2004; 545
2005; 297
1998; 709
2002; 72
2000; 746
2002; 44
1999; 340
2000; 72
2006; 163
2005; 4
1992; 19
2005; 97
1996; 5
2007; 21
2006; 313
2005; 49
2007; 45
1992; 2
1983; 33
1998; 68
Gross M (e_1_2_6_4_2) 1996; 5
e_1_2_6_20_2
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_18_2
e_1_2_6_9_2
e_1_2_6_19_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_12_2
e_1_2_6_24_2
e_1_2_6_13_2
e_1_2_6_23_2
e_1_2_6_2_2
e_1_2_6_10_2
e_1_2_6_22_2
e_1_2_6_11_2
e_1_2_6_21_2
e_1_2_6_16_2
e_1_2_6_17_2
e_1_2_6_14_2
e_1_2_6_15_2
e_1_2_6_25_2
References_xml – reference: Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 1987; 42: 157-65.
– reference: Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam. Appl. Toxicol. 1992; 19: 423-31.
– reference: Desbrow B, Hughes R, Leveritt M, Scheelings P. An examination of consumer exposure to caffeine from retail coffee outlets. Food Chem. Toxicol. 2007; 45: 1588-92.
– reference: Dudka J, Jodynis-Liebert J, Korobowicz E et al . Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: An in vitro study. Basic Clin. Pharmacol. Toxicol. 2005; 97: 74-9.
– reference: Bendriss EK, Markoglou N, Wainer IW. Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J. Chromatogr. B Biomed. Sci. Appl. 2000; 746: 331-8.
– reference: Choi JS, Li X. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int. J. Pharm. 2005; 297: 1-8.
– reference: De Vries JH, Hollman PC, Meyboom S et al . Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am. J. Clin. Nutr. 1998; 68: 60-5.
– reference: Lin SY, Tsai SJ, Wang LH, Wu MF, Lee H. Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells. Role of COX-2. Nutr. Cancer 2002; 44: 95-101.
– reference: Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 2006; 313: 144-9.
– reference: Butler MA, Lang NP, Young JF et al . Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-27.
– reference: Kang IH, Kim HJ, Oh H, Park YI, Dong MS. Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2-amino-3,5-dimethylimidazo[4,5-f]quinoline by Salmonella typhimurium TA1538 co-expressing human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and cytochrome b5. Mutat. Res. 2004; 545: 37-47.
– reference: Sharma H, Sen S, Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther. 2005; 4: 949-55.
– reference: Rahden-Staron I, Czeczot H, Szumilo M. Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin. Mutat. Res. 2001; 498: 57-66.
– reference: Caubet MS, Elbast W, Dubuc MC, Brazier JL. Analysis of urinary caffeine metabolites by HPLC-DAD. The use of metabolic ratios to assess CYP1A2 enzyme activity. J. Pharm. Biomed. Anal. 2002; 27: 261-70.
– reference: Gross M, Pfeiffer M, Martini M, Campbell D, Slavin J, Potter J. The quantitation of metabolites of quercetin flavonols in human urine. Cancer Epidemiol. Biomarkers Prev. 1996; 5: 711-20.
– reference: Yeh SL, Wu SH. Effects of quercetin on beta-apo-8′-carotenal-induced DNA damage and cytochrome P1A2 expression in A549 cells. Chem. Biol. Interact. 2006; 163: 199-206.
– reference: Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci. 2002; 72: 227-35.
– reference: Ciolino HP, Daschner PJ, Yeh GC. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999; 340: 715-22.
– reference: Pignatelli P, Pulcinelli FM, Celestini A et al . The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am. J. Clin. Nutr. 2000; 72: 1150-5.
– reference: Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al . Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses. Antimicrob. Agents Chemother. 2005; 49: 1733-8.
– reference: Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin. Pharmacol. Ther. 1983; 33: 591-602.
– reference: Krul C, Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998; 709: 27-34.
– reference: Wong P, Villeneuve G, Tessier V et al . Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J. Pharmaceut. Biomed. 2002; 28: 693-700.
– reference: Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr. 2007; 21: 190-200.
– volume: 45
  start-page: 1588
  year: 2007
  end-page: 92
  article-title: An examination of consumer exposure to caffeine from retail coffee outlets
  publication-title: Food Chem. Toxicol
– volume: 28
  start-page: 693
  year: 2002
  end-page: 700
  article-title: Stability of 5‐acetamido‐6‐formylamino‐3‐methyluracil in buffers and urine
  publication-title: J. Pharmaceut. Biomed
– volume: 27
  start-page: 261
  year: 2002
  end-page: 70
  article-title: Analysis of urinary caffeine metabolites by HPLC‐DAD. The use of metabolic ratios to assess CYP1A2 enzyme activity
  publication-title: J. Pharm. Biomed. Anal
– volume: 72
  start-page: 227
  year: 2002
  end-page: 35
  article-title: Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats
  publication-title: Life Sci
– volume: 33
  start-page: 591
  year: 1983
  end-page: 602
  article-title: Variability in caffeine metabolism
  publication-title: Clin. Pharmacol. Ther
– volume: 5
  start-page: 711
  year: 1996
  end-page: 20
  article-title: The quantitation of metabolites of quercetin flavonols in human urine
  publication-title: Cancer Epidemiol. Biomarkers Prev
– volume: 42
  start-page: 157
  year: 1987
  end-page: 65
  article-title: A urinary metabolite ratio that reflects systemic caffeine clearance
  publication-title: Clin. Pharmacol. Ther
– volume: 21
  start-page: 190
  year: 2007
  end-page: 200
  article-title: evaluation of CYP1A2, CYP2A6, NAT‐2 and xanthine oxidase activities in a Greek population sample by the RP‐HPLC monitoring of caffeine metabolic ratios
  publication-title: Biomed. Chromatogr
– volume: 340
  start-page: 715
  year: 1999
  end-page: 22
  article-title: Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially
  publication-title: Biochem. J
– volume: 498
  start-page: 57
  year: 2001
  end-page: 66
  article-title: Induction of rat liver cytochrome P450 isoenzymes CYP 1A and CYP 2B by different fungicides, nitrofurans, and quercetin
  publication-title: Mutat. Res
– volume: 163
  start-page: 199
  year: 2006
  end-page: 206
  article-title: Effects of quercetin on beta‐apo‐8′‐carotenal‐induced DNA damage and cytochrome P1A2 expression in A549 cells
  publication-title: Chem. Biol. Interact
– volume: 68
  start-page: 60
  year: 1998
  end-page: 5
  article-title: Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake
  publication-title: Am. J. Clin. Nutr
– volume: 297
  start-page: 1
  year: 2005
  end-page: 8
  article-title: Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits
  publication-title: Int. J. Pharm
– volume: 44
  start-page: 95
  year: 2002
  end-page: 101
  article-title: Protection by quercetin against cooking oil fumes‐induced DNA damage in human lung adenocarcinoma CL‐3 cells. Role of COX‐2
  publication-title: Nutr. Cancer
– volume: 19
  start-page: 423
  year: 1992
  end-page: 31
  article-title: Toxicity and carcinogenicity studies of quercetin, a natural component of foods
  publication-title: Fundam. Appl. Toxicol
– volume: 545
  start-page: 37
  year: 2004
  end-page: 47
  article-title: Biphasic effects of the flavonoids quercetin and naringenin on the metabolic activation of 2‐amino‐3,5‐dimethylimidazo[4,5‐f]quinoline by TA1538 co‐expressing human cytochrome P450 1A2, NADPH‐cytochrome P450 reductase, and cytochrome 5
  publication-title: Mutat. Res
– volume: 4
  start-page: 949
  year: 2005
  end-page: 55
  article-title: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer
  publication-title: Cancer Biol. Ther
– volume: 746
  start-page: 331
  year: 2000
  end-page: 8
  article-title: Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine
  publication-title: J. Chromatogr. B Biomed. Sci. Appl
– volume: 72
  start-page: 1150
  year: 2000
  end-page: 5
  article-title: The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide
  publication-title: Am. J. Clin. Nutr
– volume: 313
  start-page: 144
  year: 2006
  end-page: 9
  article-title: Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats
  publication-title: Int. J. Pharm
– volume: 2
  start-page: 116
  year: 1992
  end-page: 27
  article-title: Determination of CYP1A2 and NAT phenotypes in human populations by analysis of caffeine urinary metabolites
  publication-title: Pharmacogenetics
– volume: 97
  start-page: 74
  year: 2005
  end-page: 9
  article-title: Activity of NADPH–cytochrome P‐450 reductase of the human heart, liver and lungs in the presence of (–)‐epigallocatechin gallate, quercetin and resveratrol: An study
  publication-title: Basic Clin. Pharmacol. Toxicol
– volume: 49
  start-page: 1733
  year: 2005
  end-page: 8
  article-title: Should we use ‐acetyltransferase type 2 genotyping to personalize isoniazid doses
  publication-title: Antimicrob. Agents Chemother
– volume: 709
  start-page: 27
  year: 1998
  end-page: 34
  article-title: Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed‐phase high‐performance liquid chromatography
  publication-title: J. Chromatogr. B Biomed. Sci. Appl
– ident: e_1_2_6_14_2
  doi: 10.1016/j.mrfmmm.2003.08.002
– ident: e_1_2_6_24_2
  doi: 10.1016/S0731-7085(01)00546-5
– ident: e_1_2_6_21_2
  doi: 10.1038/clpt.1983.80
– ident: e_1_2_6_16_2
  doi: 10.1016/j.ijpharm.2006.01.028
– ident: e_1_2_6_5_2
  doi: 10.1016/0272-0590(92)90181-G
– ident: e_1_2_6_18_2
  doi: 10.1111/j.1742-7843.2005.pto_98.x
– ident: e_1_2_6_10_2
  doi: 10.1016/j.fct.2007.02.020
– ident: e_1_2_6_22_2
  doi: 10.1097/00008571-199206000-00003
– ident: e_1_2_6_13_2
  doi: 10.1038/clpt.1987.126
– ident: e_1_2_6_19_2
  doi: 10.1016/S1383-5718(01)00267-4
– ident: e_1_2_6_12_2
  doi: 10.1002/bmc.736
– ident: e_1_2_6_8_2
  doi: 10.1016/j.cbi.2006.08.002
– ident: e_1_2_6_2_2
  doi: 10.1093/ajcn/68.1.60
– ident: e_1_2_6_9_2
  doi: 10.1207/S15327914NC441_13
– ident: e_1_2_6_17_2
  doi: 10.1016/S0024-3205(02)02235-X
– ident: e_1_2_6_7_2
  doi: 10.1093/ajcn/72.5.1150
– ident: e_1_2_6_25_2
  doi: 10.1128/AAC.49.5.1733-1738.2005
– ident: e_1_2_6_11_2
  doi: 10.1016/S0378-4347(98)00016-4
– ident: e_1_2_6_3_2
  doi: 10.1042/bj3400715
– ident: e_1_2_6_20_2
  doi: 10.1016/S0731-7085(01)00656-2
– volume: 5
  start-page: 711
  year: 1996
  ident: e_1_2_6_4_2
  article-title: The quantitation of metabolites of quercetin flavonols in human urine
  publication-title: Cancer Epidemiol. Biomarkers Prev
– ident: e_1_2_6_6_2
  doi: 10.4161/cbt.4.9.1908
– ident: e_1_2_6_23_2
  doi: 10.1016/S0378-4347(00)00325-X
– ident: e_1_2_6_15_2
  doi: 10.1016/j.ijpharm.2004.12.004
SSID ssj0005063
Score 2.1690626
Snippet SUMMARY 1 Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of...
Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug‐metabolising enzymes. The aim of the present...
1. Quercetin, one of the most abundant natural flavonoids, has been reported to modulate the activity of several drug-metabolising enzymes. The aim of the...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 828
SubjectTerms Adolescent
Adult
Aryl Hydrocarbon Hydroxylases - metabolism
Arylamine N-Acetyltransferase - metabolism
Caffeine - metabolism
Caffeine - pharmacokinetics
Caffeine - urine
Cross-Over Studies
CYP1A2
CYP2A6
Cytochrome P-450 CYP1A2 - metabolism
Cytochrome P-450 CYP2A6
Dose-Response Relationship, Drug
Drug Interactions
Humans
Inactivation, Metabolic
Male
N-acetyltransferase
quercetin
Quercetin - administration & dosage
Quercetin - pharmacology
Time Factors
xanthine oxidase
Xanthine Oxidase - metabolism
Young Adult
Title SIMULTANEOUS ACTION OF THE FLAVONOID QUERCETIN ON CYTOCHROME P450 (CYP) 1A2, CYP2A6, N-ACETYLTRANSFERASE AND XANTHINE OXIDASE ACTIVITY IN HEALTHY VOLUNTEERS
URI https://api.istex.fr/ark:/67375/WNG-X2T0BSLQ-1/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1681.2009.05158.x
https://www.ncbi.nlm.nih.gov/pubmed/19215233
https://www.proquest.com/docview/733966863
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjpswFLWqmU03fcz0kT5GXlRRKyURYMBk6RBTqAhkwEmTFeJhNmkz1SSRJl31E_oF_bh-SW0gSTOaxajqzsJcg-1r-1z7-lwA3ilqauqlkXdThVvCQMm0bmYWSO42FRinKuJVMJhRYLoT_dPMmDX-T_IuTM0Psd9wkyOjmq_lAE-z1a1BLs8lTUttaCfF0mz1JJ6UrlsSH0UHJimjCaqGJPGm0NFjp547CzpaqU5lo9_cBUOPUW21LDmPwWJXodobZdHbrLNe_v0W1-P_qfET8KhBr5DU6vYUPODLM3BOlsJy_7qFbVj5k1Yb9WegPa5ZsbcdyA6XvFad6rU9X_b2HPyKvdHEZySg4SSGtVcLDB3IXAodn0zDIPSG8HJCI5syT2QF0J6z0HajcEThWDcU-N6ejz9AlWgdkTXWiNmBwe8fP4kQmPssIkHs0IjEFJJgCGckYK4XUBjOvGH1UHxy6rE5FIW7lPjMncNp6E8CRmkUPwPMocx2u03YiG4uwKTVxVqJUZ5ZKLN4KeBrITFSKpRSy7AwrnAuj7DLEutaauV93peMaqVoSlNPM4HW0HNwsrxa8pcAWlzT01Qplbww9FxHWckLzA2z6KMC4cxsAbzTkCRvKNVlZI8vyd-mlS7SostkwM9-UnVZctMC6l7yW00rcg-ZdqWEe4H0eiHd8rCRfA4-JjONKYPYv0zUFoA7LU3EZCFPgNIlv9qsEoyQMG8tE7XAi1p7D1_vywjHSOSYlQ7e-7cSm45l6tW_Cr4GD-sjOulV-QacrK83_K1AeuvsApySwXDgXFRj-Q_OqTa8
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLXQzAI2PGZ4lKcXqAKprZI4idOlSV0SSJ1O4pZ2FeW5maGDZlppyopP4Av4OL4E20lbOprFCLGz4lwntq_tc-3rcwF4q-mpbVZW3k210hEGSmZ0M7tAcrepwDjVUamCwYyY7U3MTzNr1oQDkndhan6I7YabHBlqvpYDXG5IXxvl8mDSdvSGd1KszU5PAMpDGeBb2VfRjkvKasKqIUm9KbR0363nxpL21qpD2exXNwHRfVyrFqbhA3C2qVLtj3LaWy2zXv79Gtvjf6rzQ3C_AbCQ1Br3CNwpF0fgmCyE8f51DdtQuZSqvfoj0B7XxNjrDuS7e16XHfXaljJ7fQx-xf5oEnDCaDiJYe3YAsMh5B6Fw4BMQxb6A3gyoZFLuS-yGHTnPHS9KBxRODYtDb5z5-P3UCdGR2SNDWJ3IPv94ycRAvOAR4TFQxqRmELCBnBGGPd8RmE48wfqofjk1OdzKAr3KAm4N4fTMJgwTmkUPwZ8SLnrdZvIEd1c4Emni40KozxzUOaUlUCwhYRJqdBLI8PCvsK5PMWuKmwaqZP3y74kVatEU9pmmgnAhp6Ag8X5onwGoFMaZppqlZYXlpmbKKvKApeWXfRRgXBmtwDeqEiSN6zqMrjHWfK3dWWKtOgyGfOzn6guS65aQN9KfquZRW4h01ZauBVIL06lZx62ki_sYzIzuPYhDk4SvQXgRk0TMV_IQ6B0UZ6vLhOMkLBwHRu1wNNafXdf78sgx0jk2EoJb_1biUvHMvX8XwXfgLseHwVJ4LPPL8C9-sROOlm-BAfLi1X5SgC_ZfZaDeg_n945ZQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjpswFLWqGanqpo-ZPtKnF1XUSkkEGDBZusQUWmIYcNJkhXhu0mZGMxNp0lU_oV_Qj-uX1AaSNKNZjKruLMzlYR_jc-3LuQC8VdTU1Csj76dKaQkHJdP6mVkgudpUYJyqqKyTwYyZ6U70TzNj1sY_yX9hGn2I7YKbHBn191oO8LOiujbI5b6kaamt7KSYmq2B4JOHuqlYEuGjaCclZbRZ1ZBU3hQg3Y_qufFKe1PVoWz1q5t46D6trecl5wFYbN6oCUdZDFaX2SD_fk3s8f-88kNwv6WvkDR4ewTulMsjcEyWwnX_toZdWAeU1iv1R6AbNrLY6x7ku7-8Lnr1aVvB7PUx-BV744nPCaPBJIZNWAsMHMhdCh2fTAMWeCN4MqGRTbknqhi05zyw3SgYUxjqhgLf2fPwPVSJ1hNVoUbMHmS_f_wkwmDu84iw2KERiSkkbARnhHHXYxQGM29UHxS3nHp8DsXFXUp87s7hNPAnjFMaxY8Bdyi33X6bN6KfCzZp9bFWYZRnFsqsshL8tZAkKRWo1DIsvCucyz3sqsK6llr5sBxKSbVKNKWpp5mga-gJOFieLstnAFqlpqepUil5Yei5jrKqLHBpmMUQFQhnZgfgDUKSvNVUl6k9viZ_-1a6KIsukxk_h0ndZclVB6hby7NGV-QWNt0ahFuD9Hwh4_KwkXxhH5OZxpUPsX-SqB0ANyhNxNdCbgGly_J0dZFghIR_a5moA5426N3dfShTHCNRY9YYvPVjJTYNZen5vxq-AXfDkZP4Hvv8AtxrtutkhOVLcHB5vipfCdZ3mb2uh_Mfq3I4HQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simultaneous+action+of+the+flavonoid+quercetin+on+cytochrome+P450+%28CYP%29+1A2%2C+CYP2A6%2C+N-acetyltransferase+and+xanthine+oxidase+activity+in+healthy+volunteers&rft.jtitle=Clinical+and+experimental+pharmacology+%26+physiology&rft.au=Chen%2C+Yao&rft.au=Xiao%2C+Peng&rft.au=Ou-Yang%2C+Dong-Sheng&rft.au=Fan%2C+Lan&rft.date=2009-08-01&rft.issn=1440-1681&rft.eissn=1440-1681&rft.volume=36&rft.issue=8&rft.spage=828&rft_id=info:doi/10.1111%2Fj.1440-1681.2009.05158.x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1870&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1870&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1870&client=summon